期刊文献+

肝细胞-胆管细胞混合型肝癌预后影响因素分析 被引量:2

Prognostic factors of hepatocellular carcinoma and cholangiocarcinoma
原文传递
导出
摘要 目的探讨肝细胞-胆管细胞混合型肝癌(combined hepatocellular-cholangiocarcinoma,cHCC-CC)的临床特点、术后生存状况及影响因素。方法回顾性分析2005-01-01-2013-12-31枣庄市立医院行手术切除的30例cHCC-CC患者临床资料,描述临床特点,并分析生存状况。结果 30例患者均经病理确诊为cHCC-CC。平均年龄(57.7±10.2)岁,中位年龄52岁。肿瘤大小为2~13cm,中位数为7cm。完整随访28例,有效随访率为93.3%。根据Kaplan-Meier生存分析,中位生存时间为18个月,中位无复发生存时间为15个月。1、3和5年生存率分别为67.8%、33.4%和24.3%,1、3和5年无复发生存率分别为58.5%、23.3%和12.1%。Cox分析结果显示,有临床症状(HR=5.1,P=0.008)、切缘阳性(HR=4.0,P=0.001)、淋巴结转移(HR=6.0,P=0.009)和脉管瘤栓(HR=2.9,P=0.019)是病死率的主要影响因素;有临床症状(HR=5.1,P=0.009)、切缘阳性(HR=6.9,P=0.006)、淋巴结转移(HR=6.6,P=0.004)和脉管瘤栓(HR=3.0,P=0.003)是复发率的主要影响因素。术后介入治疗是患者病死率(HR=0.4,P=0.015)和复发率(HR=0.5,P=0.008)的保护因素。结论 cHCC-CC预后不佳,影响cHCC-CC患者术后生存因素主要是临床症状、切缘阳性、淋巴结转移、脉管瘤栓和辅助介入治疗。 OBJECTIVE To explore the clinicalpathological features, survival and impact factors of hepatocellular carcinoma and cholangiocarcinoma(HCC-CC). METHODS Thirty patients received surgery were diagnosed with com- bined HCC-CC in Zaozhuang City Hospital during 1st Jun. 2005 and 31st Dec. 2013. The clinical records and clinicopatho- logical data were retrospectively analyzed. RESULTS All of the 30 patients were HCC-CC,whose mean age was 57.7+ 10.2, and median age was 52. The median diameter of the tumors was 7 cm(2--13 cm). Twenty-eight patients had comple- ted follow-up,and the rate of follow-up was 93.3% The median overall survival time was 18 months, while the median progression free survival time was 15 months by Kaplan-Meier analysis. The 1-,3- and 5-year survival rates were 67.8o/oo, 33.40%and 24.3% respectively. 1-,3- and 5-year relapse-free survival rates were 58.5% ,23.3% and 12.1%. Cox analysis indicated that clinical symptoms (HR = 5.1, P = 0. 008), positive surgical margin ( HR= 4.0, P = 0. 001), lymph node me- tastasis (HR=6.0,P=0. 009) and tumor embolus (HR=2.9,P=0. 019) were risk factors for mortality;Also,clinical symptoms ( HR= 5.1, P = 0. 009), positive surgical margin ( HR = 6.9, P = 0. 006), lymph node metastasis ( HR = 6.6, P= 0. 004) and tumor embolus (HR= 3.0, P= 0. 003) were risk factors for recurrence. Postoperative interventional thera- py was protective factor of mortality ( HR = 0.4, P = 0. 015) and recurrence ( HR = 0.5, P = 0. 008). CONCLUSION Lymph node metastasis,tumor embolus and postoperative interventional therapy are infected factors for the survival rate of the HCC-CC.
作者 王涛 邱梅清
出处 《中华肿瘤防治杂志》 CAS 北大核心 2015年第10期796-799,共4页 Chinese Journal of Cancer Prevention and Treatment
基金 山东省自然科学基金(2013M50030)
关键词 肝细胞-胆管细胞混合型肝癌 回顾性研究 影响因素 预后 hepatocellular carcinoma and cholangiocarcinoma retrospective studies impact factors prognosis
  • 相关文献

参考文献17

  • 1Panjala C,Senecal DL, Bridges MD, et al. The diagnostic conun-drum and liver transplantation outcome for combined hepatocel- lular-cholangiocarcinoma[J]. Am J Transplant, 2010, 10 ( 5 ) : 1263-1267.
  • 2许磊波,王捷,刘超.不同分期系统对晚期肝癌肝切除患者生存的预测价值比较[J].中国普外基础与临床杂志,2014,21(2):138-141. 被引量:7
  • 3Goodman ZD, lshak KG, Langloss J M, et al.Combined hepatoeel- lular-cholangiocarcinoma. A histologic and immunohistochemical study[J]. Cancer, 1985,55 (1) : 124-129.
  • 4储开建,陆崇德,姚晓平.肝细胞-胆管细胞混合型肝癌的诊治进展[J].中华肝胆外科杂志,2012,18(7):561-563. 被引量:11
  • 5Wachtel MS,Zhang Y,Xu T, et al. Combined hepatocellular cholangio- carcinomas;analysis of a large database[J]. Clin Med Pathol, 2008, 1 (1) :43-47.
  • 6Akiba J, Nakashima O, Hattori S, et al. Clinicopathologic analysis of combined hepatocellular-cholangiocarcinoma according to the latest WHO classification [J]. Am J Surg Pathol, 2013,37 (4) : 496-505.
  • 7Yin X, Zhang BH, Qiu SJ, et al. Combined hepatocellular carcino- ma and cholangiocarcinoma: clinical features, treatment modali- ties,and prognosis[J].Ann Surg Oneol,2012,19(9) :2869-2876.
  • 8姚占胜,毕新宇.混合型肝细胞-胆管细胞癌的外科治疗效果及预后分析[J].医学研究杂志,2012,41(5):97-101. 被引量:1
  • 9Kim KH, Lee SG, Park EH, et al. Surgical treatments and prog- noses of patients with combined hepatocellular carcinoma and cholangiocarcinoma[J]. Ann Surg Oncol, 2009,16 (3): 623-629.
  • 10Wang J,Wang F, Kessinger A. Outcome of combined hepatocel- lular and cholangiocareinoma of the liver [J]. J Oncol, 2010, 2010:917356.

二级参考文献73

  • 1Peng Yan,Lu-Nan Yan the Department of Surgery, Pittsburg Medical College of USA First People’s Hospital of Chengdu, Chengdu 610041, China Department of General Surgery, West China Hospital, Sichuan University, Chengdu 610041, China.Staging of hepatocellular carcinoma[J].Hepatobiliary & Pancreatic Diseases International,2003,2(4):491-495. 被引量:2
  • 2欧迪鹏,杨连粤,黄耿文,陶一明,丁翔,常志刚.肝细胞癌术后复发转移相关危险因素分析[J].中南大学学报(医学版),2005,30(5):540-543. 被引量:6
  • 3Louis Libbrecht.Hepatic progenitor cells in human liver tumor development[J].World Journal of Gastroenterology,2006,12(39):6261-6265. 被引量:24
  • 4Konstadoulakis MM,Roayaie S,Comatos IP,et al.Fifteen-year,singlecenter experience with the surgical management of intrahepatic cholanglocarcinoma:operative results and long-term outcome.Surgery,2008,143:366-374.
  • 5Shimada M,Yamashita Y,Aishima S,et al.Value of lymph node dissection during resection of intrahepatic cholangiocarcinoma.Br J Surg,2001,88:1463-1466.
  • 6Okami J,Dono K,Sakon M,et al.Patterns of regional lymph node involvement in intrahepatic cholangiocarcinoma of the left lobe.J Gastrointest Surg,2003,7:850-856.
  • 7Nozaki Y,Yamamoto M,Ikai I,et al.Reconsideration of the lymph node metastasis pattern (N factor) from intrahepatic cholangiocarcinoma using the International Union Against Cancer TNM staging system for primary liver carcinoma.Cancer,1998,83:1923-1929.
  • 8Uenishi T,Kube S,Yamazaki O,et al.Indications for surgical treatment of intrahepatic cholangiocarcinoma with lymph node metastases.J Hepatobiliary Pancreat Surg,2008,15:417-422.
  • 9Grobmyer SR,Wang L,Gonen M,et al.Perihepatic lymph node assessment in patients undergoing partial hepatectomy for malignancy.Ann Surg,2006,244:260-264.
  • 10Urahashi T,Yamamoto M,Ohtsubo T,et al.Hepatopancreatoduodenectomy could be allowed for patients with advanced intrahepatic cholangiocarcinoma.Hepatogastrcenterology,2007,54:346-349.

共引文献68

同被引文献25

  • 1李学民,汤萨,彭秀青,黄佳,王伟鹏,张朋,赵学科,宋昕,王苒,范宗民,雷晓雨,王立东.1973—2005年手术治疗食管癌患者5年生存率变化分析[J].肿瘤防治研究,2014,41(3):237-242. 被引量:30
  • 2韩俊庆,刘奇,梁荣祥,曲风声,颜廷秀,孙迎红,李学芹.单纯Barrett's食管腺癌108例临床分析[J].中华肿瘤杂志,2007,29(6):470-473. 被引量:1
  • 3王士杰,王其彰.食管癌与贲门癌[M].北京:人民卫生出版社,2008,189-197.
  • 4Pennathur A, Gibson MK, Jobe BA, et al. Oesophageal carcinoma [J]. Lancet,2013,381(9864) :400-412.
  • 5Fan YJ, Song X, Li JL, et al. Esophageal and gastric cardia cancers on 4 238 Chinese patients residing in municipal and rural regions: a histopathological comparison during 24-year period[J].World J Surg,2008,32(9) :1980-1988.
  • 6Kofoed SC, Muhic A, Baeksqaard L, et al. Survival after adjuvant chemoradiotherapy or surgery alone in resectable adenoearcinoma at the gastroesophageal junction[J].Scand J Surg, 2012, 101(1) :26-31.
  • 7Bedard EL, Inculet RL, Malthaner RA, et al. The role of surgery and postoperative chemoradiation therapy in patients with lymph node positive esophageal carcinoma[J]. Cancer, 2001,91 (12) :2423-2430.
  • 8Schreiber D, Rineer J, Vongtama D, et al. Impact of postoperative radiation after esophagectomy for esophageal cancer[J]. J Thorac Oncol, 2010,5(2) :244-250.
  • 9Cabau M, Luc G, Terrebonne E, et al. Lymph node invasion might have more prognostic impact than R status in advanced esophageal adenoearcinoma[J]. Am J surg,2013,205(6) :711-717.
  • 10Ku GY, Iison DH. Adjuvant (postoperative) therapy for esophageal cancer[J].Thorac Surg Clin,2013,23(4) :525-533.

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部